Hatasu Kobayashi

Dr. Hatasu Kobayashi

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
WLWanyang Liu
Wanyang Liu
DMDaisuke Morito
Daisuke Morito
STSeiji Takashima
Seiji Takashima
YMYohei Mineharu
Yohei Mineharu
HKHatasu Kobayashi
Hatasu Kobayashi
AKAkio Koizumi
Akio Koizumi
Moyamoya disease is an idiopathic vascular disorder of intracranial arteries. Its susceptibility locus has been mapped to 17q25.3 in Japanese families, but the susceptibility gene is unknown. Genome-wide linkage analysis in eight three-generation families with moyamoya disease revealed linkage to 17q25.3 (P<10-4). Fine mapping demonstrated a 1.5-Mb disease locus bounded by D17S1806 and rs2280147. We conducted exome analysis of the eight index cases in these families, with results filtered through Ng criteria. There was a variant of p.N321S in PCMTD1 and p.R4810K in RNF213 in the 1.5-Mb locus of the eight index cases. The p.N321S variant in PCMTD1 could not be confirmed by the Sanger method. Sequencing RNF213 in 42 index cases confirmed p.R4810K and revealed it to be the only unregistered variant. Genotyping 39 SNPs around RNF213 revealed a founder haplotype transmitted in 42 families. Sequencing the 260-kb region covering the founder haplotype in one index case did not show any coding variants except p.R4810K. A case-control study demonstrated strong association of p.R4810K with moyamoya disease in East Asian populations (251 cases and 707 controls) with an odds ratio of 111.8 (P = 10−119). Sequencing of RNF213 in East Asian cases revealed additional novel variants: p.D4863N, p.E4950D, p.A5021V, p.D5160E, and p.E5176G. Among Caucasian cases, variants p.N3962D, p.D4013N, p.R4062Q and p.P4608S were identified. RNF213 encodes a 591-kDa cytosolic protein that possesses two functional domains: a Walker motif and a RING finger domain. These exhibit ATPase and ubiquitin ligase activities. Although the mutant alleles (p.R4810K or p.D4013N in the RING domain) did not affect transcription levels or ubiquitination activity, knockdown of RNF213 in zebrafish caused irregular wall formation in trunk arteries and abnormal sprouting vessels. We provide evidence suggesting, for the first time, the involvement of RNF213 in genetic susceptibility to moyamoya disease.

1 July 2011 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
HKHatasu Kobayashi
Hatasu Kobayashi
KAKoji Abe
Koji Abe
TMTohru Matsuura
Tohru Matsuura
YIYoshio Ikeda
Yoshio Ikeda
THToshiaki Hitomi
Toshiaki Hitomi
AKAkio Koizumi
Akio Koizumi

5 January 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Kouji H. HaradaKouji H. Harada
Kouji H. Harada
KTKeiko Tanaka
Keiko Tanaka
HSHiroko Sakamoto
Hiroko Sakamoto
MIMie Imanaka
Mie Imanaka
TNTamon Niisoe
Tamon Niisoe
AKAkio Koizumi
Akio Koizumi
Neonicotinoids, which are novel pesticides, have entered into usage around the world because they are selectively toxic to arthropods and relatively non-toxic to vertebrates. It has been suggested that several neonicotinoids cause neurodevelopmental toxicity in mammals. The aim was to establish the relationship between oral intake and urinary excretion of neonicotinoids by humans to facilitate biological monitoring, and to estimate dietary neonicotinoid intakes by Japanese adults. Deuterium-labeled neonicotinoid (acetamiprid, clothianidin, dinotefuran, and imidacloprid) microdoses were orally ingested by nine healthy adults, and 24 h pooled urine samples were collected for 4 consecutive days after dosing. The excretion kinetics were modeled using one- and two-compartment models, then validated in a non-deuterium-labeled neonicotinoid microdose study involving 12 healthy adults. Increased urinary concentrations of labeled neonicotinoids were observed after dosing. Clothianidin was recovered unchanged within 3 days, and most dinotefuran was recovered unchanged within 1 day. Around 10% of the imidacloprid dose was excreted unchanged. Most of the acetamiprid was metabolized to desmethyl-acetamiprid. Spot urine samples from 373 Japanese adults were analyzed for neonicotinoids, and daily intakes were estimated. The estimated average daily intake of these neonicotinoids was 0.53–3.66 μg/day. The highest intake of any of the neonicotinoids in the study population was 64.5 μg/day for dinotefuran, and this was <1% of the acceptable daily intake.

17 July 2015 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
HKHatasu Kobayashi
Hatasu Kobayashi
YMYoshiko Matsuda
Yoshiko Matsuda
THToshiaki Hitomi
Toshiaki Hitomi
HOHiroko Okuda
Hiroko Okuda
HSHirotomo Shioi
Hirotomo Shioi
AKAkio Koizumi
Akio Koizumi
Background: P.R4810K of RNF 213 (mysterin: rs112735431), which is an AAA + ATP ase, is the susceptibility polymorphism for moyamoya disease ( MMD ) in East Asians. However, the role of RNF 213 R4810K in the etiology of MMD is unknown. Methods and Results: To clarify the role of RNF 213 in known angiogenic pathways, RNF 213 expression was analyzed in endothelial cells ( EC s) treated with several angiogenic and antiangiogenic factors, including interferons ( IFN s). RNF 213 was upregulated by IFN ‐β through signal transducer and activator of transcription x in the promoter and mediated antiangiogenic activity of IFN ‐β. RNF 213 wild‐type ( WT ) overexpression could not lower angiogenesis without IFN ‐β, but RNF 213 R4810K overexpression could. To correlate biochemical function as ATP ase and the role of RNF 213 oligomer formation with antiangiogenic activity, we investigated the effects of mutations in the AAA + module. A mutation of the Walker B motif ( WEQ ), which stabilizes oligomerization, inhibited angiogenesis, but AAA + module deletion, which cannot initiate oligomerization, did not. Intriguingly, R4810K, similar to WEQ , decreased ATP ase activity, suggesting its antiangiogenic activity through stabilizing oligomers. To confirm the antiangiogenic effect of RNF 213 upregulation in vivo, vascular EC ‐ or smooth muscle cell‐specific Rnf213 R4757K (R4810K ortholog) or WT transgenic (Tg) mice were exposed to hypoxia. Cerebral angiogenesis by hypoxia was suppressed in EC‐specific Rnf213 R4757K Tg mice, whereas it was not suppressed in other mice. Conclusions: This study suggests the importance of inflammatory signals as environmental factors and R4810K carriers for susceptibility to cerebral hypoxia. A specific inhibitor of ATP binding to the first AAA + could be a promising therapeutic candidate for MMD .

10 December 2015 in Environmental Health and Preventive Medicine
Verified
Journal Article
Open access
PDF file
AKAkio Koizumi
Akio Koizumi
HKHatasu Kobayashi
Hatasu Kobayashi
THToshiaki Hitomi
Toshiaki Hitomi
KHKouji H. Harada
Kouji H. Harada
THToshiyuki Habu
Toshiyuki Habu
SYShohab Youssefian
Shohab Youssefian
The cerebrovascular disorder moyamoya disease (MMD) was first described in 1957 in Japan, and is typically considered to be an Asian-specific disease. However, it is globally recognized as one of the major causes of childhood stroke. Although several monogenic diseases are known to be complicated by Moyamoya angiopathy, the ring finger protein 213 gene (RNF213) was identified as a susceptibility gene for MMD. RNF213 is unusual, because (1) it induces MMD with no other recognizable phenotypes, (2) the RNF213 p.R4810K variant is an Asian founder mutation common to Japanese, Korean and Chinese with carrier rates of 0.5–2 % of the general population but a low penetrance, and (3) it encodes a relatively largest proteins with a dual AAA+ ATPase and E3 Ligase activities. In this review, we focus on the genetics and genetic epidemiology of RNF213, the pathology of RNF213 R4810K, and the molecular functions of RNF213, and also address the public health contributions to current unresolved issues of MMD. We also emphasize the importance of a more updated definition for MMD, of qualified cohort studies based on genetic epidemiology and an awareness of the ethical issues associated with genetic testing of carriers.

1 January 2012 in Neurologia medico-chirurgica
Verified
Journal Article
Open access
PDF file
WLWanyang Liu
Wanyang Liu
THToshiaki Hitomi
Toshiaki Hitomi
HKHatasu Kobayashi
Hatasu Kobayashi
Kouji H. HaradaKouji H. Harada
Kouji H. Harada
AKAkio Koizumi
Akio Koizumi
Moyamoya disease is an idiopathic vascular disorder of the intracranial arteries. Ring finger 213 (RNF213) was previously identified as the strongest susceptibility gene for moyamoya disease in East Asian people by a genome-wide linkage analysis and exome analysis. The coding variant p.R4810K in RNF213 was strongly associated with moyamoya disease in the Japanese (odds ratio: 338.94, p = 1.05 × 10−100) and Korean (odds ratio: 135.63, p = 7.59 × 10−27) populations, and much less strongly associated in the Chinese population (odds ratio: 14.70, p = 2.63 × 10−5). The present study investigated the distribution of variant p.R4810K in RNF213 in 2,508 participants from East and Southeast Asian countries using a TaqMan probe. p.R4810K was detected at an allele frequency of about 1.00% in 4 of 11 investigated locations in China. In contrast, p.R4810K was detected homogeneously at relatively high frequencies of 1.00-1.72% in all investigated locations in Korea and Japan, including Okinawa. p.R4810K was not detected in Southeast Asian populations. The population susceptible to moyamoya disease was estimated to be 16.16 million people in East Asian countries, including 11.41 million Chinese, 1.36 million Korean, and 3.39 million Japanese people. The number of patients with moyamoya disease, which was estimated at approximately one per 300 carriers of p.R4810K, was considered to be 53,800 in East Asian populations.